Chattem completes acquisition
This article was originally published in The Rose Sheet
Executive Summary
Chattem announces Jan. 2 it has closed its agreement to purchase, for $410 mil. in cash, the U.S. rights to five brands divested in connection with Johnson & Johnson's acquisition of Pfizer's Consumer Healthcare business, including anti-cavity mouthwash brand ACT (1"The Rose Sheet" Oct. 9, 2006, In Brief). "We are very excited to add these leading brands to the company's existing portfolio of quality products," Chattem CEO and Chairman Zan Guerry says. Chattem will replace Fidelity Bankshares in Standard & Poor's SmallCap 600 index after the close of trading Jan. 5...
You may also be interested in...
Chattem’s Core Brands Off To Strong Start In Fiscal ’08; Firm Ups Projections
Chattem has up-adjusted its 2008 earnings estimates following a strong start to the year and with high expectations for product initiatives to come
Chattem Boosts Acquired Brands With Ad Spend, Retail Expansion
Chattem's strategy of growing recently acquired brands through aggressive marketing and distribution expansion is paying off, President and COO Robert Bosworth indicated Sept. 5 at the Lehman Brothers Back-to-School Consumer Conference
Listerine fluoride rinse
McNeil's new Listerine Tooth Defense "strengthen[s] tooth enamel and protect[s] against cavities" while eradicating "the germs that cause oral malodor so patient's breath feels fresh and clean throughout the day," according to the company, which further characterizes the product as a "great recommendation for patients 12 and above who need help in the fight against cavities." Available in Mint-Shield flavor, Listerine Tooth Defense costs between $3.29 and $5.89, depending on the size. Johnson & Johnson gained the brand through its $16.6 bil. acquisition of Pfizer Consumer Healthcare in December. Its ACT fluoride rinse was divested at that time and picked up by Chattem (1"The Rose Sheet" Jan. 8, 2007, In Brief)...